The effect of mitomycin C on superficial bladder cancer

M. S. Soloway, W. M. Murphy, M. D. DeFuria, S. Crooke, P. Finebaum

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.

Original languageEnglish
Pages (from-to)646-648
Number of pages3
JournalJournal of Urology
Volume125
Issue number5
StatePublished - Aug 17 1981
Externally publishedYes

Fingerprint

Mitomycin
Urinary Bladder Neoplasms
Carcinoma in Situ
Cell Biology
Neoplasms
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., Murphy, W. M., DeFuria, M. D., Crooke, S., & Finebaum, P. (1981). The effect of mitomycin C on superficial bladder cancer. Journal of Urology, 125(5), 646-648.

The effect of mitomycin C on superficial bladder cancer. / Soloway, M. S.; Murphy, W. M.; DeFuria, M. D.; Crooke, S.; Finebaum, P.

In: Journal of Urology, Vol. 125, No. 5, 17.08.1981, p. 646-648.

Research output: Contribution to journalArticle

Soloway, MS, Murphy, WM, DeFuria, MD, Crooke, S & Finebaum, P 1981, 'The effect of mitomycin C on superficial bladder cancer', Journal of Urology, vol. 125, no. 5, pp. 646-648.
Soloway MS, Murphy WM, DeFuria MD, Crooke S, Finebaum P. The effect of mitomycin C on superficial bladder cancer. Journal of Urology. 1981 Aug 17;125(5):646-648.
Soloway, M. S. ; Murphy, W. M. ; DeFuria, M. D. ; Crooke, S. ; Finebaum, P. / The effect of mitomycin C on superficial bladder cancer. In: Journal of Urology. 1981 ; Vol. 125, No. 5. pp. 646-648.
@article{330826f89f914169bee61b55533cdb3b,
title = "The effect of mitomycin C on superficial bladder cancer",
abstract = "A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.",
author = "Soloway, {M. S.} and Murphy, {W. M.} and DeFuria, {M. D.} and S. Crooke and P. Finebaum",
year = "1981",
month = "8",
day = "17",
language = "English",
volume = "125",
pages = "646--648",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of mitomycin C on superficial bladder cancer

AU - Soloway, M. S.

AU - Murphy, W. M.

AU - DeFuria, M. D.

AU - Crooke, S.

AU - Finebaum, P.

PY - 1981/8/17

Y1 - 1981/8/17

N2 - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.

AB - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019432928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019432928&partnerID=8YFLogxK

M3 - Article

C2 - 6785454

AN - SCOPUS:0019432928

VL - 125

SP - 646

EP - 648

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -